BR112023020371A2 - Anticorpo anti-adgre2 humanizado ou fragmento de ligação ao antígeno do mesmo, método de tratamento de um câncer, composição farmacêutica, sequência de ácido nucleico, vetor, célula isolada, e, método de tratamento de câncer - Google Patents
Anticorpo anti-adgre2 humanizado ou fragmento de ligação ao antígeno do mesmo, método de tratamento de um câncer, composição farmacêutica, sequência de ácido nucleico, vetor, célula isolada, e, método de tratamento de câncerInfo
- Publication number
- BR112023020371A2 BR112023020371A2 BR112023020371A BR112023020371A BR112023020371A2 BR 112023020371 A2 BR112023020371 A2 BR 112023020371A2 BR 112023020371 A BR112023020371 A BR 112023020371A BR 112023020371 A BR112023020371 A BR 112023020371A BR 112023020371 A2 BR112023020371 A2 BR 112023020371A2
- Authority
- BR
- Brazil
- Prior art keywords
- cancer
- treatment
- adgre2
- antibody
- vector
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 5
- 201000011510 cancer Diseases 0.000 title abstract 4
- 239000012634 fragment Substances 0.000 title abstract 4
- 108091028043 Nucleic acid sequence Proteins 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 title abstract 2
- 102000036639 antigens Human genes 0.000 title abstract 2
- 108091007433 antigens Proteins 0.000 title abstract 2
- 150000007523 nucleic acids Chemical group 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 102000037865 fusion proteins Human genes 0.000 abstract 2
- 108020001507 fusion proteins Proteins 0.000 abstract 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
anticorpo anti-adgre2 humanizado ou fragmento de ligação ao antígeno do mesmo, método de tratamento de um câncer, composição farmacêutica, sequência de ácido nucleico, vetor, célula isolada, e, método de tratamento de câncer. anticorpos, fragmentos dos mesmos e proteínas de fusão que se ligam especificamente a adgre2 são descritos, bem como métodos de produção e uso de tais anticorpos. tais anticorpos, proteínas de fusão e fragmentos dos mesmos são úteis para o tratamento e diagnóstico de várias doenças autoimunes e cânceres incluindo, por exemplo, leucemia mieloide aguda.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163179756P | 2021-04-26 | 2021-04-26 | |
| PCT/US2022/026161 WO2022232035A1 (en) | 2021-04-26 | 2022-04-25 | Anti-adgre2 antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023020371A2 true BR112023020371A2 (pt) | 2024-02-06 |
Family
ID=81648880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023020371A BR112023020371A2 (pt) | 2021-04-26 | 2022-04-25 | Anticorpo anti-adgre2 humanizado ou fragmento de ligação ao antígeno do mesmo, método de tratamento de um câncer, composição farmacêutica, sequência de ácido nucleico, vetor, célula isolada, e, método de tratamento de câncer |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230018888A1 (pt) |
| EP (1) | EP4330283A1 (pt) |
| JP (1) | JP2024518776A (pt) |
| KR (1) | KR20240004287A (pt) |
| CN (1) | CN117580860A (pt) |
| AR (1) | AR125450A1 (pt) |
| AU (1) | AU2022266583A1 (pt) |
| BR (1) | BR112023020371A2 (pt) |
| CA (1) | CA3214355A1 (pt) |
| CO (1) | CO2023013195A2 (pt) |
| EC (1) | ECSP23088752A (pt) |
| IL (1) | IL307940A (pt) |
| TW (1) | TW202305003A (pt) |
| WO (1) | WO2022232035A1 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024089622A1 (en) * | 2022-10-25 | 2024-05-02 | Takeda Pharmaceutical Company Limited | Adgre2 chimeric receptor nk cell compositions and methods of use |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| ATE68013T1 (de) | 1985-07-05 | 1991-10-15 | Whitehead Biomedical Inst | Expression von fremdem genetischem material in epithelzellen. |
| JP3015383B2 (ja) | 1987-09-11 | 2000-03-06 | ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ | 形質導入した線維芽およびそれらの使用 |
| JP2914692B2 (ja) | 1987-12-11 | 1999-07-05 | ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ | 内皮細胞の遺伝子修飾 |
| JP2917998B2 (ja) | 1988-02-05 | 1999-07-12 | ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ | 修飾された肝細胞およびその用途 |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| ES2096750T3 (es) | 1990-10-31 | 1997-03-16 | Somatix Therapy Corp | Vectores retroviricos utiles para la terapia genica. |
| CA2110799A1 (en) | 1991-06-14 | 1992-12-23 | Arnold H. Horwitz | Microbially-produced antibody fragments and their conjugates |
| JP4157160B2 (ja) | 1991-12-13 | 2008-09-24 | ゾーマ テクノロジー リミテッド | 改変抗体可変領域の調製のための方法 |
| SE9201984D0 (sv) | 1992-06-29 | 1992-06-29 | Pharmacia Biosensor Ab | Improvement in optical assays |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| US5308341A (en) | 1993-09-28 | 1994-05-03 | Becton, Dickinson And Company | Method of testing the dose accuracy of a medication delivery device |
| US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
| US5773019A (en) | 1995-09-27 | 1998-06-30 | The University Of Kentucky Research Foundation | Implantable controlled release device to deliver drugs directly to an internal portion of the body |
| US6146361A (en) | 1996-09-26 | 2000-11-14 | Becton Dickinson And Company | Medication delivery pen having a 31 gauge needle |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| CA2286879C (en) | 1997-04-14 | 2003-12-16 | Peter Kufer | Novel method for the production of anti-human antigen receptors and uses thereof |
| AU7467898A (en) | 1997-04-21 | 1998-11-13 | Arch Development Corporation | Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial cr signal and induce clonal anergy |
| US6302855B1 (en) | 1998-05-20 | 2001-10-16 | Novo Nordisk A/S | Medical apparatus for use by a patient for medical self treatment of diabetes |
| US6192891B1 (en) | 1999-04-26 | 2001-02-27 | Becton Dickinson And Company | Integrated system including medication delivery pen, blood monitoring device, and lancer |
| US6277099B1 (en) | 1999-08-06 | 2001-08-21 | Becton, Dickinson And Company | Medication delivery pen |
| PE20011227A1 (es) | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
| ATE547080T1 (de) | 2000-08-30 | 2012-03-15 | Univ Johns Hopkins | Vorrichtungen zur intraokularen arzneimittelabgabe |
| EP2357187A1 (en) | 2000-12-12 | 2011-08-17 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| ES2393282T3 (es) | 2001-09-12 | 2012-12-20 | Becton, Dickinson And Company | Dispositivo de pluma basado en microaguja para la administración de fármacos |
| US20050271660A1 (en) | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
| US20040102469A1 (en) | 2002-09-13 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Method for reducing the mortality rate |
| GB0222023D0 (en) | 2002-09-21 | 2002-10-30 | Aventis Pharma Ltd | Inhaler |
| FR2849436B1 (fr) | 2002-12-27 | 2007-01-05 | Patrick Frayssinet | Particules et ceramiques de phosphates de calcium pour transfection in vivo et in vitro |
| US20060167435A1 (en) | 2003-02-18 | 2006-07-27 | Adamis Anthony P | Transscleral drug delivery device and related methods |
| US8163881B2 (en) | 2005-05-31 | 2012-04-24 | The Board Of Regents Of The University Of Texas System | Immunoglobulin molecules with improved characteristics |
| US20090110679A1 (en) | 2007-07-13 | 2009-04-30 | Luk-Chiu Li | Methods and compositions for pulmonary administration of a TNFa inhibitor |
| BR112012022917A2 (pt) | 2010-03-11 | 2017-01-10 | Pfizer | anticorpos com ligação a antígeno dependente de ph |
| EP2622074B1 (en) | 2010-09-30 | 2014-11-12 | Board Of Trustees Of Northern Illinois University | Library-based methods and compositions for introducing molecular switch functionality into protein affinity reagents |
| EP2635674A4 (en) * | 2010-11-05 | 2014-11-05 | Transbio Ltd | MARKERS FOR ENDOTHELIAL STORAGE CELLS AND USES THEREOF |
| WO2014087010A1 (en) | 2012-12-07 | 2014-06-12 | Ablynx N.V. | IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE |
| CN108430516A (zh) * | 2015-11-19 | 2018-08-21 | 艾伯维施特姆森特克斯有限责任公司 | 新颖抗emr2抗体和使用方法 |
| EP3344263A4 (en) * | 2016-08-04 | 2020-07-01 | Memorial Sloan-Kettering Cancer Center | CANCER ANTIQUES AND USES THEREOF |
-
2022
- 2022-04-25 US US17/728,598 patent/US20230018888A1/en active Pending
- 2022-04-25 WO PCT/US2022/026161 patent/WO2022232035A1/en active Application Filing
- 2022-04-25 CA CA3214355A patent/CA3214355A1/en active Pending
- 2022-04-25 JP JP2023565453A patent/JP2024518776A/ja active Pending
- 2022-04-25 AR ARP220101068A patent/AR125450A1/es unknown
- 2022-04-25 EP EP22723302.0A patent/EP4330283A1/en active Pending
- 2022-04-25 KR KR1020237034369A patent/KR20240004287A/ko unknown
- 2022-04-25 CN CN202280030498.9A patent/CN117580860A/zh active Pending
- 2022-04-25 AU AU2022266583A patent/AU2022266583A1/en active Pending
- 2022-04-25 BR BR112023020371A patent/BR112023020371A2/pt unknown
- 2022-04-25 IL IL307940A patent/IL307940A/en unknown
- 2022-04-25 TW TW111115646A patent/TW202305003A/zh unknown
-
2023
- 2023-10-03 CO CONC2023/0013195A patent/CO2023013195A2/es unknown
- 2023-11-23 EC ECSENADI202388752A patent/ECSP23088752A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022266583A9 (en) | 2023-10-26 |
| AR125450A1 (es) | 2023-07-19 |
| JP2024518776A (ja) | 2024-05-02 |
| CO2023013195A2 (es) | 2023-10-19 |
| EP4330283A1 (en) | 2024-03-06 |
| IL307940A (en) | 2023-12-01 |
| AU2022266583A1 (en) | 2023-10-19 |
| WO2022232035A1 (en) | 2022-11-03 |
| ECSP23088752A (es) | 2024-01-31 |
| US20230018888A1 (en) | 2023-01-19 |
| CN117580860A (zh) | 2024-02-20 |
| CA3214355A1 (en) | 2022-11-03 |
| TW202305003A (zh) | 2023-02-01 |
| KR20240004287A (ko) | 2024-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201990781A1 (ru) | Анти-steap2 антитела, конъюгаты антитело-лекарственное средство и биспецифические антигенсвязывающие молекулы, которые связывают steap2 и cd3, и их применение | |
| BR112019023992A2 (pt) | Anticorpo ou fragmento de ligação ao antígeno do mesmo, seu método de produção, seus usos, bem como molécula de ácido nucleico, vetor de clonagem ou expressão, célula hospedeira, hibridoma, composição farmacêutica e imunoconjugado | |
| MX2022009306A (es) | Loseta de nucleo de espuma densificada (dfc) con linea de anticuerpos de dominio individual de cd28 y constructos multivalentes y multiespecíficas de los mismos. | |
| BR112018007046A2 (pt) | anticorpo isolado ou fragmento de ligação a antígeno, composição farmacêutica, molécula de polinucleotídeo isolado, vetor, célula, e, métodos para inibir o crescimento de um tumor ou de uma célula tumoral e para tratar uma doença ou distúrbio. | |
| BR112018075737A2 (pt) | anticorpo, composição, célula isolada, e, métodos para tratar câncer ou infecção em um paciente e para detectar expressão de pd-l1 em uma amostra. | |
| MD3353212T2 (ro) | Anticorpi bispecifici anti-CD3 optimizați și utilizările acestora | |
| SG10201906762YA (en) | Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123 | |
| BRPI0214137B8 (pt) | anticorpo monoclonal humano ou porção de ligação a antígeno do mesmo que se liga especificamente ao cd40 humano e o ativa, linhagem celular de hibridoma isolado, composição farmacêutica compreendendo os mesmos, uso dos mesmos na fabricação de um medicamento e método de fabricação dos referidos anticorpos ou porção de ligação a antígeno do mesmo | |
| BR112022001460A2 (pt) | Moléculas de ligação ao antígeno biespecíficas, um ou mais polinucleotídeos isolados, célula hospedeira, método para produzir uma molécula de ligação ao antígeno biespecífica e para tratar uma doença em um indivíduo, composição farmacêutica, uso da molécula de ligação ao antígeno biespecífica e invenção | |
| BRPI0607757A2 (pt) | anticorpo, composição, imunoconjugado, molécula bi-especìfica, molécula de ácido nucleico isolado, vetor de expressão, célula hospedeira, hibridoma, método para preparar um anticorpo anti-psma, e, usos de um anticorpo, ou porção de ligação a antìgeno do mesmo | |
| MX2019009119A (es) | Conjugados de farmacos y anticuerpos anti-ccr7. | |
| MX2022000652A (es) | Anticuerpos contra claudina 18 y metodos de tratamiento del cancer. | |
| MX2022006230A (es) | Anticuerpos contra cd3 y bcma, y proteinas de union biespecificas hechas a partir de estos. | |
| MX2020011588A (es) | Anticuerpos de alta afinidad a pd-1 y lag-3 y proteinas de union bispecificas preparadas a partir de las mismas. | |
| WO2018129090A1 (en) | Native human antibodies for immune checkpoint modulation targets tim-3 and b7-h3 | |
| MX2022010665A (es) | Anticuerpos que se unen al receptor de interleucina 4 (il4r) y usos de los mismos. | |
| MX2021012962A (es) | Anticuerpo monoclonal que se une especificamente a gitr. | |
| BR112023016121A2 (pt) | Anticorpo triespecífico que direciona bcma, gprc5d e cd3 | |
| BR112023020371A2 (pt) | Anticorpo anti-adgre2 humanizado ou fragmento de ligação ao antígeno do mesmo, método de tratamento de um câncer, composição farmacêutica, sequência de ácido nucleico, vetor, célula isolada, e, método de tratamento de câncer | |
| BR112022005114A2 (pt) | Anticorpo, composição farmacêutica, métodos para tratar câncer e para produzir um conjugado anticorpo-fármaco e um anticorpo, ácido nucleico, vetor, célula hospedeira, e, conjugado anticorpo-fármaco | |
| BR112023020365A2 (pt) | Anticorpo anti-clec12a ou fragmento de ligação ao antígeno, método de tratamento de um câncer, composição farmacêutica, sequência de ácidos nucleicos, vetor, célula, e, método de tratamento de câncer | |
| BR112023019484A2 (pt) | Anticorpo triespecífico que tem como alvo cd79b, cd20 e cd3 | |
| Lee | Molecular-level antibody repertoire profiling and engineering: Implications for developing next-generation diagnostics, therapeutics, and vaccines | |
| BR112022003471A2 (pt) | Sistema receptor de antígeno quimérico e usos do mesmo | |
| BR112022021450A2 (pt) | O cd19 ou fragmento de ligação, método de tratamento de um câncer, composição farmacêutica, ácido nucleico, vetor, e, célula isolada |